(Q26996510)

title

Defining response to anti-VEGF therapies in neovascular AMD (English)

0 references

author

Usha Chakravarthy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Faruque Ghanchi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Jonathan M Gibson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Andrew J Lotery

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1

W M Amoaku

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

R Gale

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M Gavin

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S Harding

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

R L Johnston

8

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S Mahmood

11

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

G Menon

12

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S Sivaprasad

13

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Talks

14

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Tufail

15

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Y Yang

16

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S P Kelly

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

June 2015

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

29

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

721-731

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

Ranibizumab for neovascular age-related macular degeneration

9 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Current anti-vascular endothelial growth factor dosing regimens: benefits and burden

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Time trends in the incidence and causes of blindness in Israel

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Smoking and age-related macular degeneration: a review of association.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Growth factors in age-related macular degeneration: pathogenic and therapeutic implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4469673

Incidence of legal blindness from age-related macular degeneration in denmark: year 2000 to 2010.

31 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

The effect of daily use of brimonidine tartrate on the dark-adapted pupil diameter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Bevacizumab tachyphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Tachyphylaxis and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

The Neovascular Age-Related Macular Degeneration Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2015.48

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

21 January 2018

1 reference

12 December 2020

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

1 reference

12 December 2020

The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model

1 reference

12 December 2020

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

12 December 2020

Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration

1 reference

12 December 2020

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration

1 reference

12 December 2020

Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity

1 reference

12 December 2020

Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients

1 reference

12 December 2020

Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment

1 reference

12 December 2020

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

1 reference

12 December 2020

Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes

1 reference

12 December 2020

[Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis®): the key to success]

1 reference

12 December 2020

Identifiers

DOI

10.1038/EYE.2015.48

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 June 2020

1042569072

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882328%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

PubMed publication ID

25882328

2 references